ADMS - Adamas Pharmaceuticals, Inc.
5.59 0.00 (0.00%)
After hours: 4:29PM EDT
| Previous Close | 5.16 |
| Open | 5.23 |
| Bid | 5.56 x 1000 |
| Ask | 7.55 x 1100 |
| Day's Range | 5.23 - 5.61 |
| 52 Week Range | 4.20 - 29.49 |
| Volume | 484,157 |
| Avg. Volume | 391,876 |
| Market Cap | 153.911M |
| Beta (3Y Monthly) | 2.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.61 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.33 |
- Simply Wall St.•10 hours ago
Should You Worry About Adamas Pharmaceuticals, Inc.'s (NASDAQ:ADMS) CEO Salary Level?
In 2000 Gregory Went was appointed CEO of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). This analysis aims first to...
- Zacks•10 hours ago
Allergan (AGN) in Focus: Stock Moves 6.2% Higher
Allergan (AGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Benzinga•yesterday
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals ...
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of ADMS earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Adamas Pharmaceuticals Inc Earnings Call
- Zacks•2 days ago
What Makes Adamas (ADMS) a New Buy Stock
Adamas (ADMS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire•3 days ago
ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (ADMS), including investors who purchased Adamas common stock directly in the Company’s January 24, 2018 secondary public offering (“SPO”). Adamas investors who wish to learn more about the investigation should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
- GlobeNewswire•3 days ago
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.
NEW YORK, June 17, 2019 -- Levi & Korsinsky reminds investors that it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM:.
- ACCESSWIRE•7 days ago
INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 12, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- GlobeNewswire•8 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (ADMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. In January 2018, Adamas completed a secondary public offering (“SPO”), issuing approximately 3 million shares of common stock priced at $41.50 per share. In October 2018, Merrill Lynch released a study which cast serious doubt on the ability of Gocovri, Adamas’s treatment for dyskinesia in Parkinson’s disease patients treated with levodopa therapy, to achieve a sizeable market share and emphasized that Adamas had failed to include critical information. In March 2019, Adamas backtracked on prior issued growth estimates and no longer made predictions regarding Gocovri’s ability to achieve a sizeable market share. Adamas’s stock price has fallen sharply since the SPO and now trades well below the offering price.
- ACCESSWIRE•9 days ago
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 11, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, ...
- ACCESSWIRE•10 days ago
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 10, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, ...
- Business Wire•10 days ago
ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (ADMS) directly in the Company’s January 24, 2018 secondary public offering (“SPO”). If you purchased Adamas common stock directly in the SPO, you may move the Court for appointment as lead plaintiff.
- GlobeNewswire•13 days ago
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 148,500 shares of the company’s common stock, at a per share exercise price of $4.67, the closing trading price on June 7, 2019, and restricted stock units to acquire 74,250 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- GlobeNewswire•16 days ago
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Adamas knew it faced serious roadblocks that would inhibit its ability to sell its new drug, Gocovri.
- ACCESSWIRE•17 days ago
ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm
NEW YORK, NY / ACCESSWIRE / June 3, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or the ...
- GlobeNewswire•17 days ago
Adamas to Present at Upcoming JMP Investor Conference
EMERYVILLE, Calif., June 03, 2019 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central.
- GlobeNewswire•20 days ago
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Adamas knew it faced serious roadblocks that would inhibit its ability to sell its new drug, Gocovri.
- GlobeNewswire•21 days ago
Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as its Chief Commercial Officer, leading all commercial functions including Marketing, Sales, Access, and Analytics. “We are very pleased to welcome such an accomplished and experienced leader as Vijay to Adamas,” said Gregory Went, CEO of Adamas.
- Business Wire•22 days ago
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Adamas knew it faced serious roadblocks that would inhibit its ability to sell its new drug, Gocovri.
- ACCESSWIRE•22 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adamas Pharmaceuticals, Inc. (ADMS)
NEW YORK, NY / ACCESSWIRE / May 29, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") ...
